WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,533 shares of the biopharmaceutical company’s stock, valued at approximately $1,152,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. California Public Employees Retirement System boosted its stake in Alnylam Pharmaceuticals by 5.0% in the second quarter. California Public Employees Retirement System now owns 211,581 shares of the biopharmaceutical company’s stock valued at $68,994,000 after buying an additional 10,100 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 22.6% in the 2nd quarter. Federated Hermes Inc. now owns 323,842 shares of the biopharmaceutical company’s stock valued at $105,602,000 after purchasing an additional 59,669 shares in the last quarter. Jump Financial LLC grew its holdings in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. Jump Financial LLC now owns 17,177 shares of the biopharmaceutical company’s stock valued at $5,601,000 after purchasing an additional 1,460 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, First Trust Advisors LP increased its position in Alnylam Pharmaceuticals by 39.5% during the 2nd quarter. First Trust Advisors LP now owns 251,817 shares of the biopharmaceutical company’s stock worth $82,115,000 after purchasing an additional 71,357 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 2.6%

NASDAQ ALNY opened at $404.46 on Thursday. The firm has a market capitalization of $53.43 billion, a PE ratio of 1,685.25 and a beta of 0.30. The business’s 50-day moving average price is $454.49 and its two-hundred day moving average price is $405.65. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Analysts Set New Price Targets

ALNY has been the topic of a number of research analyst reports. Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Truist Financial upped their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Royal Bank Of Canada raised their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Evercore ISI upped their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Finally, HC Wainwright set a $570.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $482.71.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 60,328 shares of company stock valued at $27,288,993 over the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.